R. Desikan

发表

Antitumor activity of thalidomide in refractory multiple myeloma.

B. Barlogie, N. Munshi, S. Singhal, 1999, The New England journal of medicine.

Optimizing dendritic cell‐based immunotherapy in multiple myeloma

B. Barlogie, N. Munshi, R. Desikan, 2002, British journal of haematology.

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

B. Barlogie, R. Desikan, N. Munshi, 2002, Leukemia.

Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications

B. Barlogie, L. Fink, R. Desikan, 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

High‐dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia

B. Barlogie, S. Jagannath, N. Munshi, 1999, British journal of haematology.

Relation of Anemia to Diastolic Heart Failure and the Effect on Outcome

B. Barlogie, R. Desikan, P. Roberson, 2004 .

Malignant pleural effusion of multiple myeloma: Prognostic factors and outcome

B. Barlogie, R. Desikan, E. Anaissie, 2005, Leukemia & lymphoma.

Nephrotic proteinuria associated with high‐dose pamidronate in multiple myeloma

S. Jagannath, R. Desikan, Yu. G. Veksler, 2002, British journal of haematology.

Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy

B. Barlogie, S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

Results of autologous stem cell transplant in multiple myeloma patients with renal failure

B. Barlogie, R. Desikan, E. Anaissie, 2001, British journal of haematology.

Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years

B. Barlogie, N. Munshi, R. Desikan, 2001, British journal of haematology.

Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis

R. Desikan, Anthony Kunnumpurath, S. Desikan, 2020, Journal of investigative medicine high impact case reports.

Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response

R. Desikan, Shifang Wang, S. Desikan, 2020, EJHaem.

Vitamin A and Hydrochlorothiazide Causing Severe Hypercalcemia in a Patient With Primary Hyperparathyroidism

R. Desikan, T. Weaver, R. Varghese, 2019, Journal of investigative medicine high impact case reports.

Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience

B. Barlogie, S. Jagannath, D. Siegel, 2003, British journal of haematology.

Infection – an underappreciated cause of bone pain in multiple myeloma

B. Barlogie, S. Jagannath, N. Munshi, 2003, British journal of haematology.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

J Shaughnessy, B. Barlogie, J. Shaughnessy, 2001, Blood.

in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities,

B. Barlogie, J. Shaughnessy, S. Jagannath, 2013 .

study of 169 patients single-agent thalidomide: identification of prognostic factors in a phase 2 Extended survival in advanced and refractory multiple myeloma after

B. Barlogie, J. Shaughnessy, N. Munshi, 2013 .

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

F. Zhan, B. Barlogie, J. Shaughnessy, 2003, Blood.

Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants

B. Barlogie, N. Munshi, R. Desikan, 2002, British journal of haematology.

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2000, Blood.

Erratum: Antitumor activity of thalidomide in refractory multiple myeloma (New England Journal of Medicine (November 18, 1999) 341 (1565-1571))

B. Barlogie, D. Siegel, N. Munshi, 2000 .

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.

B. Barlogie, J. Mehta, R. Desikan, 2001, Blood.

Capillary Leak Syndrome From Rituximab Therapy of Lymphoma

R. Desikan, K. Vedala, S. Desikan, 2020, Journal of investigative medicine high impact case reports.

Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

B. Barlogie, D. Siegel, R. Desikan, 2002, British journal of haematology.

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Faith Davies, Edie Weller, Kenneth Anderson, 2004, Mayo Clinic proceedings.

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

B. Barlogie, L. Fink, R. Desikan, 2001, Blood.

Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients

B. Barlogie, R. Desikan, E. Anaissie, 2002, British journal of haematology.

Advances in Immunology: A Cornerstone in Diagnosis and Therapy of Merkel Cell Carcinoma

R. Desikan, Shiyu Wang, J. Mclaughlin, 2022, Journal of investigative medicine high impact case reports.

Acute hyponatremia from immune checkpoint inhibitor therapy for non–small cell lung cancer

R. Desikan, R. Varghese, Roy Kamoga, 2020, Postgraduate Medical Journal.

A rare case of chordoma presenting as a Pancoast tumor

R. Desikan, K. Vedala, P. Sobash, 2021, Rare tumors.

Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.

S. Jagannath, R. Desikan, 2001, Seminars in oncology.